Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib

NCT00820417 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Head and Neck Cancer
Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Cetuximab/Gefitinib combination and/or monotherapy

Sponsor

Harrison Clinical Research

Collaborators

[object Object]
[object Object]